Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback